Lactalis USA Opens Culinary & Sensory Institute as Hub to Advance Culinary Expertise and Ensure Product Quality
New facility in Buffalo, New York is a center of excellence to drive innovation, quality and enhance the customer and consumer experience with the company's dairy products
BUFFALO, N.Y., Jan. 28, 2025 (GLOBE NEWSWIRE) -- Lactalis USA announces the opening of its Culinary & Sensory Institute in Buffalo, New York, a facility designed to help expand its culinary expertise in multiple channels. The new institute is a center of excellence for Lactalis' North American culinary and sensory channel operations for fostering innovation, enhancing customer and consumer experiences with the company's dairy products and testing product quality. Lactalis USA is a subsidiary of Lactalis, the world's largest dairy company.
'The Culinary & Sensory Institute exemplifies our commitment to providing delicious, nutritious dairy products that resonate with the evolving tastes and demands of our consumers,' said Esteve Torrens, Lactalis USA CEO. 'It allows us to monitor the quality and performance of products from across our U.S. portfolio and ensure their consistency. Our U.S. business has grown steadily since entering the market in 1980 and this institute helps fulfill a key aspect of our future growth strategy by continuing to drive improvement.'
'Our institute maximizes the impact of our culinary sales operations by deepening our customer relationships,' added Jean-Luc Bruandet, president & CEO of Lactalis American Group, a division of Lactalis USA that oversees food service sales. 'The Culinary & Sensory Institute allows us to work in collaboration with key partners to create recipes and collect feedback that will ensure our products fulfill their needs and expectations. It aligns with our vision to drive relevant dairy innovation to stay ahead of consumer trends and produce the highest quality products for our customers and consumers.'
The Culinary & Sensory Institute comprises commercial and residential kitchen spaces where Lactalis chefs actively address customer and consumer needs by hosting customers to explore innovative ways to expand menu and retail offerings using equipment found in restaurants and home kitchens. Lactalis chefs also create new recipes and concepts in the institute and further foster dairy product innovation. Additionally, the institute is a central location for sensory panels to sample Lactalis products for quality assurance and compare them against competing brands.
The institute represents a $2 million investment in Buffalo, where the company has invested more than $111 million since 2020 including projects to modernize its manufacturing facility and increase its production of Galbani® Mozzarella, Ricotta and whey powder.
About Lactalis in Buffalo, N.Y. Lactalis has operated in Buffalo since 1992 and currently produces Galbani® Ricotta, Mozzarella and Provolone, whey powder and President® Brie cut-and-wrap at its manufacturing facility on South Park Ave. Galbani cheese is the Official Cheese of the Buffalo Bills and is a brand more than 140 years old. Lactalis annually produces more than 280 million pounds of dairy products in Buffalo and collects more than 700 million pounds of milk annually, supporting more than 150 local dairy farms. Lactalis employs more than 700 people in Buffalo at two corporate offices and a manufacturing facility.
About Lactalis USA Lactalis USA is committed to enriching lives by producing nutritious and great tasting dairy products. The company offers an unrivaled house of beloved dairy brands in the United States including Galbani® Italian cheeses, Président® specialty cheeses and gourmet butters, Kraft® brands in natural and grated cheeses, Breakstones® cottage cheese, ricotta and sour cream, Cracker Barrel® cheese, Black Diamond® cheddar cheese, Parmalat® milk, siggi's® and Stonyfield Organic® yogurt brands. In the United States the company has approximately 4,000 employees, is present in eight states with 11 manufacturing facilities and corporate offices located in New York City and Buffalo, N.Y., Chicago, Ill., Bedford, N.H., and San Fernando, Calif. Lactalis USA is part of Lactalis Group, the world's leading dairy company, a French family business founded in 1933 in Laval, France.
For more information, visit https://lactalisamericangroup.com/, www.lactalisheritagedairy.com, www.lactalisyogurtusa.com and www.karouncheese.com. Follow Lactalis USA on Instagram and like us on Facebook.
###
CONTACT: Don Heins Lactalis USA don.heins@us.lactalis.comSign in to access your portfolio
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
2 hours ago
- Business Upturn
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer
U.S. FDA approves third indication of darolutamide for patients with advanced prostate cancer Darolutamide is the first and only in the U.S. and FDA-approved androgen receptor inhibitor (ARi) for the treatment of patients with hormone-sensitive prostate cancer (mHSPC), in combination with androgen deprivation therapy (ADT), with or without chemotherapy. This third approval is based on positive results from the pivotal Phase III ARANOTE trial and broadens the indication profile of darolutamide in mHSPC, enabling its use in combination with ADT, with or without chemotherapy (docetaxel). Darolutamide plus ADT reinforces the established safety and tolerability profile of darolutamide for prostate cancer patients across all approved indications. Orion's collaboration partner Bayer announced today that the U.S. Food and Drug Administration (FDA) has approved the oral androgen receptor inhibitor (ARi) darolutamide in combination with androgen deprivation therapy (ADT) for use in patients with metastatic castration-sensitive prostate cancer (mCSPC), which is also known as metastatic hormone-sensitive prostate cancer (mHSPC). The approval is based on positive results from the pivotal Phase III ARANOTE trial, which showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001) in patients with mHSPC. With this approval, darolutamide plus ADT is indicated in the U.S. for the treatment of adult patients with mHSPC either with or without docetaxel. In addition, darolutamide is approved for the treatment of adult patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease. Prostate cancer is the second most common cancer in men and the fifth most common cause of cancer death in men worldwide.1 In 2022, an estimated 1.5 million men were diagnosed with prostate cancer, and about 397,000 died from the disease worldwide.1 Prostate cancer diagnoses are projected to increase to 2.9 million by 2040.2 Darolutamide, under the brand name Nubeqa®, is already approved in mHSPC in combination with ADT and docetaxel in over 85 markets around the world. It's also approved in combination with ADT for the treatment of patients with non-metastatic castration-resistant prostate cancer (nmCRPC) who are at high risk of developing metastatic disease in more than 85 countries around the world. An approval process in the EU for the treatment of mHSPC in combination with ADT (without docetaxel) is already underway by Bayer. Nubeqa achieved blockbuster status in September 2024, with annual sales reported by Bayer reaching EUR 1.52 billion for the full year of 2024. Darolutamide is developed jointly by Orion and Bayer. About the ARANOTE trial The ARANOTE trial is a randomized, double-blind, placebo-controlled Phase III study designed to assess the efficacy and safety of darolutamide plus ADT in patients with mHSPC. 669 patients were randomized 2:1 to receive 600 mg of darolutamide twice daily or matching placebo in addition to ADT. The primary endpoint of this study is rPFS, measured as time from randomization to date of first documented radiological progressive disease or death due to any cause, whichever occurs first. Secondary endpoints include overall survival (time to death from any cause), time to first castration resistant event, time to initiation of subsequent anti-cancer therapy, time to prostate-specific antigen (PSA) progression, PSA undetectable rates, time to pain progression, and safety assessments. Results from the Phase III ARANOTE trial presented at ESMO 2024 and published in The Journal of Clinical Oncology showed that darolutamide plus ADT significantly reduced the risk of radiological progression or death by 46% compared to placebo plus ADT (HR 0.54; 95% CI 0.41–0.71; P<0.0001), in patients with mHSPC. Consistent benefits in radiological progression-free survival (rPFS) were observed across prespecified subgroups, including patients with high-volume (HR 0.60, 95% CI: 0.44-0.80) and low-volume (HR 0.30, 95% CI: 0.15-0.60) mHSPC. The incidence of adverse events in the treatment group with darolutamide plus ADT in the ARANOTE study was comparable to placebo plus ADT. Darolutamide plus ADT was generally well tolerated and showed lower discontinuation rates due to adverse events compared to placebo plus ADT. About darolutamide Darolutamide is an oral ARi with a unique chemical structure that binds with high affinity to the androgen receptor and exhibits a strong antagonistic effect against the androgen receptor inhibiting the receptor function and the growth of prostate cancer cells. Additionally, preclinical models and neuroimaging data in healthy humans support darolutamide's low potential for blood-brain barrier penetration. Darolutamide (plus ADT or plus ADT and docetaxel) demonstrated a side effect profile in both registrational studies in mHSPC where the incidences of adverse events were roughly similar to the respective comparator arm. Darolutamide is a treatment option for doctors and patients, considering its tolerability and low risk of drug interaction. A robust clinical development program is underway investigating darolutamide across various stages of prostate cancer. The program includes the Phase III ARASTEP trial evaluating darolutamide plus ADT compared to ADT alone in hormone-sensitive high-risk biochemical recurrence (BCR) prostate cancer, who have no evidence of metastatic disease by conventional imaging and a positive PSMA PET/CT at baseline. Furthermore, darolutamide is also being investigated by Bayer in the collaborative Phase III DASL-HiCaP (ANZUP1801) trial led by the Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP). The study evaluates darolutamide as an adjuvant treatment for localized prostate cancer with very high risk of recurrence. About metastatic hormone-sensitive prostate cancer At the time of diagnosis, most men have localized prostate cancer, meaning their cancer is confined to the prostate gland and can be treated with curative surgery or radiotherapy. mHSPC is a stage in the disease where the cancer has spread outside of the prostate to other parts of the body. Up to 10% of men will present with mHSPC when first diagnosed.3,4,5 For patients with mHSPC, ADT is the cornerstone of treatment, in combination with chemotherapy docetaxel and/or an androgen receptor inhibitor (ARi). Despite treatment, most men with mHSPC will eventually progress to castration-resistant prostate cancer (CRPC), a condition with limited survival. Contact person: Tuukka Hirvonen, Investor Relations tel. +358 10 426 2721 References Bray F et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. Accessed: September 2024. James ND et al. Lancet 2024; 403: 1683–722. Piombino C et al. Cancers (Basel). 2023 Oct 11;15(20):4945. Helgstrand JT et al. Cancer. 2018;124(14):2931-2938. Buzzoni C et al. Eur. Urol. 2015;68:885–890. Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finland Orion is a globally operating Nordic pharmaceutical company – a builder of well-being for over a hundred years. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and consumer health products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. In 2024 Orion's net sales amounted to EUR 1,542 million and the company employed about 3,700 professionals worldwide, dedicated to building well-being. Orion's A and B shares are listed on Nasdaq Helsinki. Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same. GlobeNewswire provides press release distribution services globally, with substantial operations in North America and Europe.
Miami Herald
3 hours ago
- Miami Herald
Ultra-Rare BMW 507 For Sale With Eye-Popping Pricetag
You can never go wrong with a vintage BMW. The German automaker's classic examples have a special way of combining slim bodylines and a svelte silhouette with sheer, menacing performance under the hood. This 1959 BMW 5078 Series II on Bring a Trailer is a perfect example of what I mean. When US importer Max Hoffman suggested that BMW design as mid-level sports car for the North American market, BMW replied with the 507. Featuring hand-built aluminum bodywork styled by Albrecht von Goertz, the 507 debuted in 1955 at the Waldorf Astoria Hotel in New York City before entering production in late 1956. In 1957, the Series II debuted with a smaller fuel tank relocated from behind the seats to inside the trunk to prevent fumes from entering the cabin. This particular example, Chassis 70185, is one of only 252 built during the model's three years of production and was completed on October 6, 1958 as a Feather White car before being delivered new on October 31, 1958, to Autohaus H. Bäte KG in Hannover, Germany. The car reportedly underwent a refurbishment around 2012 that included a repaint in its current shade of Coral Red and a refinishing of its hardtop in an ivory color. The 507 was then acquired in 2022 by German specialists Arthur Bechtel Classic Motors, who re-trimmed the interior in tan leather. What sets this particular BMW 507 apart from others is its ivory hardtop that can be installed when the beige convertible top is not in use. Hardtops were optional equipment at the time and were hand-built to fit each car's hand-built bodywork, making them particularly rare and special accessories to own. Under the hood is a 3,168cc V8 with an aluminum block and cylinder heads as well as twin Zenith carburetors mated to a four-speed manual transmission. This 507 sits on 16" Rudge wheels wrapped in 6.00-16 Michelin Pilote X tires with Dunlop front disc and rear drum brakes behind them. The cabin still wears its tan leather and sports a contrasting ivory steering wheel and shift knob alongside a Becker Mexico radio. The odometer shows around 33,000 kilometers (~21,000 miles), with 25 of those being added by the current owner. The auction ends in 9 days with a current bid of $1,000,000, so it's unlikely that you and I will be able to afford such a beauty. Considering that it was purchased from a collection by its current owner in January 2025 and they only added 25 miles since, this poor thing suffers from a severe lack of being driven. This isn't an uncommon occurence with cars of this rarity and value, but it's also not an excuse. I won't go on a tangent about why driving your cars is the right thing to do, but I sure hope that the new owner feels the same way. Copyright 2025 The Arena Group, Inc. All Rights Reserved.
Yahoo
3 hours ago
- Yahoo
Appian Connected Claims 2.0 Transforms Insurance Claims Management with AI
Appian is named a 'Leader' in Everest Group's 'AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix®' for 2025 LONDON, June 4, 2025 /PRNewswire/ -- Appian (NASDAQ: APPN) today announced the launch of Connected Claims 2.0, an AI-powered solution designed to provide a unified claims workflow. Everest Group also named Appian a Leader in AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. Connected Claims 2.0 leverages Appian's Case Management Studio, AI agents, and data fabric to offer streamlined, data-driven, and AI-powered automated processes. Driven by rapid digital transformation, the global insurance claims services processing market is projected to reach $638.3 billion by 2032. Connected Claims 2.0 will support insurers through this growth with a unified claims workflow that accelerates processing, enhances fraud detection, combats inconsistent handling, data management issues and improves customer satisfaction. Connected Claims 2.0 offers a fully integrated, AI-powered platform with customisable workflows and a superior user experience, featuring a single pane of glass, AI-powered data insights, real-time data access, and automated regulatory compliance management. Appian's Connected Claims solution brings powerful AI-driven support to every adjuster, making it easier to manage the demands of a document-heavy claims environment. With capabilities like data classification, document summarisation, contextual chat, and next-best-action recommendations, AI accelerates work and improves decision-making. The next generation of the solution introduces the Appian AI Document Centre, enabling users to easily train models to extract data from unstructured documents. This means faster intake, more accurate data capture, and seamless handoff for tasks like fraud detection and automated triage. Over time, users can achieve high accuracy and boost straight-through processing (STP) rates—freeing human experts to focus only on the most complex cases. The result is faster, smarter claims handling with less manual work. Trusted by companies like Aon, Canada Life, and Aviva, Appian has also been named a Leader in Everest Group's AI-enabled Claims Management Systems for Property & Casualty (P&C) Insurance – Products PEAK Matrix® Assessment 2025. The assessment considered several factors, including each provider's vision and strategy, technology capabilities, deployment flexibility, customer engagement models, support services, and overall value delivered. Appian's recognition as a Leader highlights its strength in embedding AI directly into processes. This approach enables insurers to easily access powerful AI capabilities exactly when and where they're needed—with just a few clicks. "Appian's Connected Claims solution, built on its low-code platform, combines AI-driven document processing, seamless third-party integrations, and configurable accelerators to deliver rapid time-to-value for P&C insurers," said Aurindum Mukherjee, Practice Director at Everest Group. "Strong integration support across payment, risk, and fraud systems, coupled with proven success driving accelerated business value for insurers and high client satisfaction for implementation and support, underpins Appian's position as a Leader in Everest Group's AI-enabled Claims Management Systems PEAK Matrix® Assessment 2025." "We are launching Appian Connected Claims 2.0 to meet the urgent need for speed and early value realisation as the insurance industry tackles complexity, " said Jake Sloan, Global Vice President of Insurance, Appian. "Our solution drives digital-first claims innovation, aligning with core admin cloud modernisation for early value realisation. It's configurable, rapidly deployable, and leverages the latest powerful AI in Process to accelerate cycles, combat fraud, and personalise customer experiences. Connected Claims 2.0 empowers insurers to transform operations, balancing efficiency and accuracy with superior customer satisfaction, truly leading the evolution of claims management." Connected Claims 2.0 supports insurance companies, from claims adjusters, fraud detection teams, customer service representatives, regulatory compliance teams, to IT and operations teams. About Appian Appian is The Process Company. We deliver a software platform that helps organisations run better processes that reduce costs, improve customer experiences, and gain a strategic edge. Committed to client success, we serve many of the world's largest companies across various industries. For more information, visit [Nasdaq: APPN] Follow Appian: LinkedIn, X (Twitter) DisclaimerLicensed extracts taken from Everest Group's PEAK Matrix® Reports, may be used by licensed third parties for use in their own marketing and promotional activities and collateral. Selected extracts from Everest Group's PEAK Matrix® reports do not necessarily provide the full context of our research and analysis. All research and analysis conducted by Everest Group's analysts and included in Everest Group's PEAK Matrix® reports is independent and no organization has paid a fee to be featured or to influence their ranking. To access the complete research and to learn more about our methodology, please visit Everest Group PEAK Matrix® Reports. About Everest GroupEverest Group is a leading global research firm helping business leaders make confident Group's PEAK Matrix® assessments provide the analysis and insights enterprises need to make critical selection decisions about global services providers, locations, and products and solutions within various market segments. Likewise, providers of these services, products, and solutions, look to the PEAK Matrix® to gauge and calibrate their offerings against others in the industry or market. Find further details and in-depth content at View original content: SOURCE Appian Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
